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Since hyperinsulinaemia may promote obesity-linked cancers, we compared type 2 diabetes prevalence among oesophageal
adenocarcinoma (OAC) patients and population controls. Diabetes increased the risk of OAC (adjusted odds ratio 1.59, 95% confidence
interval (CI) 1.04–2.43), although the risk was attenuated after further adjusting for body mass index (1.32, 95% CI 0.85–2.05).
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Adenocarcinomas of the oesophagus (OAC) and gastro-oesopha-
geal junction (GOJAC) have been rising rapidly in incidence in
many countries (Blot et al, 1991; Wayman et al, 2001; Pohl and
Welch, 2005), widely attributed to the steadily rising prevalence of
obesity (Silventoinen et al, 2004; Reeves et al, 2007; Whiteman
et al, 2007; Corley et al, 2008).
One proposed mechanism to explain the association between
obesity and OAC is that obesity increases the risk of OAC through
the pathway of gastro-oesophageal acid reflux. However, we and
others have shown that obesity is strongly associated with OAC
(Corley et al, 2008) even among people with no history of reflux
(Chow et al, 1998; Whiteman et al, 2007), arguing against
increased exposure to acid as being the sole mechanism for the
observed phenomenon. A second postulated mechanism is that the
metabolic changes accompanying adiposity establish a hormonal
milieu that promotes the development of nascent tumours (Calle
and Kaaks, 2004).
A candidate hormone central to the ‘metabolic hormonal
hypothesis’ is insulin. Insulin activates the insulin receptor,
triggering intracellular signalling cascades with mitogenic and
antiapoptotic effects (Calle and Kaaks, 2004). In addition, its
positive feedback influences levels of leptin, a mitogenic adipo-
cytokine that has been implicated in cancers of the colon, breast
and prostate (Tessitore et al, 2000; Stattin et al, 2003). If
hyperinsulinaemia is positively associated with the risk of OAC,
then an association with type 2 diabetes (a proxy for pre-existing
hyperinsulinaemia) should be observed, independently of other
obesity-related factors.
Although some studies investigated oesophageal cancer in
relation to diabetes, only three distinguished adenocarcinomas
from squamous cell carcinomas (Cheng et al, 2000; Reavis et al,
2004; Rubenstein et al, 2005). For each study, however, the
prevalence of diabetes among controls was markedly different
from prevailing population estimates. We therefore used data from
a large population-based case–control study to explore the
hypothesis and address some gaps in the evidence.
METHODS
The study was approved by the human research ethics committees
of the Queensland Institute of Medical Research and participating
hospitals and we obtained written informed consent from all
participants. Details of recruitment and data collection have been
reported earlier (Whiteman et al, 2007). Briefly, patients (cases)
with a primary invasive OAC or oesophageal squamous cell
carcinoma (OSCC) or diagnosed between 1 July 2001 and 30 June
2005 were recruited through major treatment centres and state-
based cancer registries throughout mainland Australia. In all, 1102
patients returned questionnaires (75% of those meeting the
inclusion criteria and invited to take part: 367 OAC, 426 GOJAC
and 309 OSCC).
Potential controls were randomly selected from the Australian
electoral roll (enrolment is compulsory), matched to the distribu-
tion of the case-series by age, sex and state of residence. Completed
questionnaires were returned by 1580 controls (52% of all controls
meeting the inclusion criteria).
Data were collected through self-completed questionnaires
about education, occupation, smoking, medication use, maximum
weight and height and weight 1 year ago. We calculated BMI by
dividing weight in kilograms by the square of height in metres.
Participants were asked about the frequency of symptoms of
gastro-oesophageal reflux. For analysis, we defined ‘frequent
symptoms’ as those occurring at least weekly.
Diabetes was self-reported using the questions ‘Have you ever
had diabetes treated with insulin injections?’ and ‘Have you ever
had diabetes treated with tablets and/or diet?’ A positive response
to either of these questions prompted a question about the age of
diagnosis. We classified those who reported diabetes treated only
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ywith tablets/diet as having type 2 diabetes. Participants who had
insulin-treated diabetes were considered to have type 2 diabetes if
they were diagnosed after the age of 25 years.
Details of the histological type and anatomical site of each
tumour were abstracted from diagnostic pathology reports.
Tumours were categorised according to the WHO classification
as ‘oesophageal’ or of the ‘gastro-oesophageal junction’ (Spechler
et al, 2000). We calculated the odds ratios (ORs) and 95%
confidence intervals (95% CIs) associated with diabetes using
multivariable logistic regression analysis in SAS version 9.1 (SAS
Institute Inc., Cary, NC). We first fitted models that contained
terms for diabetes, age and sex (Model 1). We then estimated risks
associated with diabetes adjusted for these variables and educa-
tion, smoking, frequency of aspirin use and frequency of gastro-
oesophageal reflux symptoms (Model 2). Finally, we fitted models
comprising the preceding variables as well as BMI (Model 3).
RESULTS
The demographic and clinical characteristics of cases and controls
have been reported earlier (Sadeghi et al, 2008). Diabetes was self-
reported by 7% of controls, compared with 14, 12 and 4% of cases
who had OAC, GOJAC and OSCC, respectively.
In simple models adjusted only for age and sex, we found a
significant increase in the risk of OAC associated with diabetes
(Model 1: OR 1.78, 95% CI 1.22–2.62) that was somewhat
attenuated by adjustment for additional factors (Table 1). Adding
the term for BMI to the model further attenuated the estimate, with
the final OR suggesting a 32% increase in risk of OAC associated
with diabetes, although this increase was no longer statistically
significant (Model 3: OR 1.32, 95% CI 0.85–2.05). Similar patterns
were observed for GOJAC, although the magnitude of association
was smaller. There was some suggestion that people whose
diabetes had been diagnosed greater than 10 years before their
adenocarcinoma had a greater risk than those whose onset of
diabetes was more recent (Table 1).
We observed consistently higher risks of OAC among those with
diabetes within each category of BMI. People with diabetes who
were also obese were at a 3.5-fold higher risk of OAC than those
with neither risk factor (OR 3.55, 95% CI 1.87–6.76). Oesophageal
adenocarcinoma risks were somewhat lower in those with either
obesity or diabetes alone (obese OR 2.67, 95% CI 1.80–3.96;
diabetes OR 1.86, 95% CI 0.65–5.31). In contrast to OAC, the odds
of OSCC were significantly lower in people with diabetes compared
with those without (OR 0.54, 95% CI 0.29–1.0) (Table 1).
DISCUSSION
Obesity is an established risk factor for OAC, although the precise
mechanism involved remains unknown. An emerging hypothesis is
that metabolic aberrations accompanying obesity lead to changes
in hormones and cytokines, including insulin. We indirectly tested
this ‘metabolic hormonal hypothesis’ by comparing the diabetes
prevalence among oesophageal cancer patients with population
controls, and found that those with adenocarcinoma were more
likely than controls to report a history of diabetes. The association
was greater for long-standing diabetes than for more recent
diagnoses. In contrast, we found the suggestion of an inverse
association between diabetes and OSCC.
The risk estimates generated by different multivariable models
warrant comment. As excess body fat leads to high levels of insulin
(and eventually to diabetes) and as diabetes is a proxy measure for
hyperinsulinaemia, the inclusion of terms for both of these factors
in the same model may underestimate the real effect of
hyperinsulinaemia. One could argue that the effect of hyperinsu-
linaemia is best estimated by Model 2, which adjusts the
association between diabetes and OAC for factors that might
explain the confounding effect of BMI (e.g., gastro-oesophageal
Table 1 Relative risks for adenocarcinomas of the oesophagus (OAC), gastro-oesophageal junction (GOJAC) and squamous cell carcinoma (OSCC)
associated with type 2 diabetes; minimally, partially and fully adjusted for confounding factors
History of type 2 diabetes Control (N) Case (N) OR (95% CI)
a OR (95% CI)
b OR (95% CI)
c
OAC
No diabetes 1423 293 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 46 1.78 (1.22–2.62) 1.59 (1.04–2.43) 1.32 (0.85–2.05)
No diabetes 1423 293 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes duration o10 years 68 25 1.46 (0.90–2.38) 1.39 (0.82–2.36) 1.14 (0.66–1.97)
Diabetes duration X10 years) 30 18 2.45 (1.32–4.57) 1.96 (0.97–3.97) 1.65 (0.80–3.40)
P-trend 0.18
GOJAC
No diabetes 1423 338 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 44 1.56 (1.06–2.28) 1.44 (0.96–2.16) 1.23 (0.82–1.87)
No diabetes 1423 338 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes (duration o10 years) 68 20 1.06 (0.63–1.79) 0.90 (0.57–1.71) 0.87 (0.50–1.51)
Diabetes (duration X10 years) 30 22 2.76 (1.55–4.91) 2.46 (1.33–4.55) 2.16 (1.16–4.04)
P-trend 0.07
OSCC
No diabetes 1423 270 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes 103 12 0.54 (0.29–1.0) 0.48 (0.25–0.91) 0.57 (0.30–1.10)
No diabetes 1423 270 1.0 (ref) 1.0 (ref) 1.0 (ref)
Diabetes (duration o10 years) 68 7 0.49 (0.22–1.08) 0.42 (0.18–0.97) 0.52 (0.23–1.20)
Diabetes (duration X10 years) 30 5 0.73 (0.28–1.92) 0.62 (0.23–1.67) 0.70 (0.25–1.93)
P-trend 0.17
CI¼confidence interval; OR¼odds ratio.
aOR: Model 1: adjusted for age (in years) and sex.
bOR: Model 2: adjusted for age (in years), education level, cumulative smoking
history, frequency of gastro-oesophageal reflux symptoms 10 years before diagnosis and frequency of aspirin use in the last 5 years.
cOR: Model 3: as for Model 2 with an
additional term for BMI.
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linaemia (Rothman, 2002).
To address potential selection bias in controls, we compared the
age-specific prevalence of diabetes in our control group with that
reported in the population-based Australian Diabetes Survey
(Dunstan et al, 2001) and found a very high concordance. Patients
may have lost weight before their diagnosis, so we performed all
analyses using maximum reported BMI, with negligible difference
in the results.
We found only three earlier studies that investigated the
association between diabetes and OAC (Cheng et al, 2000; Reavis
et al, 2004; Rubenstein et al, 2005). Of these, one found a
substantial and significant increase in risk of OAC with diabetes
(Reavis et al, 2004), one reported an OR of close to one
(Rubenstein et al, 2005) and the third a highly unstable risk
estimate of 7.00 (95% CI 0.85–56.89) (Cheng et al, 2000). In all
three studies, the prevalence of diabetes among controls was
different from population estimates, raising concerns about
generalisability.
In summary, our data support the hypothesis that diabetes is
associated with an increased risk of OAC and that this is unlikely
to be due entirely to other factors associated with a high BMI.
Resolution of this question requires a further analysis of existing
or new population-based data sets, in which histological subtypes
are treated as separate entities.
ACKNOWLEDGEMENTS
We thank Harish Babu, MD, for his assistance with pathology
abstractions. This study was supported by the Cancer Council
Queensland and the National Health and Medical Research Council
(NHMRC) of Australia (program no. 199600). Rachel Neale,
Penelope Webb and David Whiteman are supported by Research
Fellowships from the National Health and Medical Research
Council of Australia. The funding bodies played no role in the
design or conduct of the study; the collection, management,
analysis or interpretation of the data; or preparation, review or
approval of the paper.
REFERENCES
Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF (1991) Rising incidence of
adenocarcinoma of the esophagus and gastric cardia. JAMA 265:
1287–1289
Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological
evidence and proposed mechanisms. Nat Rev Cancer 4: 579–591
Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari
P, Ahmed A, Day NE (2000) A case–control study of oesophageal
adenocarcinoma in women: a preventable disease. Br J Cancer 83: 127–132
Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL,
Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB,
Rotterdam H, Niwa S, Fraumeni Jr JF (1998) Body mass index and risk of
adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst
90: 150–155
Corley DA, Kubo A, Zhao W (2008) Abdominal obesity and the risk of
esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers
Prev 17: 352–358
Dunstan DW, Zimmet PZ, Welborn TA, Sicree R, Armstrong T, Atkins R,
Cameron A, Shaw J, Chadban S, Committee AS (2001) Diabesity and
Associated Disorders in Australia – 2000. The Accelerating Epidemic.
International Diabetes Institute: Melbourne
Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in
the marked increase of esophageal adenocarcinoma incidence. J Natl
Cancer Inst 97: 142–146
Reavis KM, Morris CD, Gopal DV, Hunter JG, Jobe BA (2004)
Laryngopharyngeal reflux symptoms better predict the presence of
esophageal adenocarcinoma than typical gastroesophageal reflux symp-
toms. Ann Surg 239: 849–856; discussion 856–8
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer
incidence and mortality in relation to body mass index in the Million
Women Study: cohort study. BMJ 335: 1134
Rothman KJ (2002) Epidemiology. An Introduction. Oxford University
Press: New York
Rubenstein JH, Davis J, Marrero JA, Inadomi JM (2005) Relationship
between diabetes mellitus and adenocarcinoma of the oesophagus and
gastric cardia. Aliment Pharmacol Ther 22: 267–271
Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC (2008)
Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of
cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17:
1169–1178
Silventoinen K, Sans S, Tolonen H, Monterde D, Kuulasmaa K,
Kesteloot H, Tuomilehto J (2004) Trends in obesity and energy
supply in the WHO MONICA Project. Int J Obes Relat Metab Disord
28: 710–718
Spechler S, Dixon M, Genta R (2000) Adenocarcinoma of the oesophago-
gastric junction. In Pathology and Genetics of Tumours of the Digestive
System. WHO Classification of Tumours, SR H, LA A (eds) Vol. 2 IARC
Press: Lyon
Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B,
Hallmans G, Kaaks R, Olsson T (2003) Plasma leptin and colorectal
cancer risk: a prospective study in Northern Sweden. Oncol Rep 10:
2015–2021
Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM,
Benedetto C, Mussa A (2000) Leptin expression in colorectal and breast
cancer patients. Int J Mol Med 5: 421–426
Wayman J, Forman D, Griffin SM (2001) Monitoring the changing pattern
of esophago-gastric cancer: data from a UK regional cancer registry.
Cancer Causes Control 12: 943–949
Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb
PM, Green AC (2007) Combined effects of obesity, acid reflux and smoking
on the risk of adenocarcinomas of the oesophagus. Gut 57: 173–180
Appendix
The Australian Cancer Study: Oesophageal Cancer Contributors
Investigators: David C Whiteman MBBS, PhD, Penelope M
Webb MA, D Phil, Adele C Green MBBS, PhD, Nicholas K Hayward
PhD, Peter G Parsons PhD and David M Purdie PhD.
Clinical collaborators: B Mark Smithers FRACS, David Gotley
FRACS PhD, Andrew Clouston FRACP PhD and Ian Brown
FRACP.
Project manager: Suzanne Moore RN, MPH.
Research nurses: Suzanne O’Brien RN MPH, Ellen Minehan RN,
Deborah Roffe RN, Sue O’Keefe RN, Suzanne Lipshut RN, Gabby
Connor RN, Hayley Berry RN, Frances Walker RN, Teresa Barnes
RN, Janine Thomas RN, Linda Terry RN MPH, Michael Connard B
Sc, Leanne Bowes B Sc, MaryRose Malt RN and Jo White RN.
Database: Karen Harrap BIT and Troy Sadkowski BIT.
Clinical contributors:
Australian Capital Territory: Charles Mosse FRACS, Noel Tait
FRACS New South Wales: Chris Bambach FRACS, Andrew
Biankan FRACS, Roy Brancatisano FRACS, Max Coleman
FRACS, Michael Cox FRACS, Stephen Deane FRACS, Gregory
L Falk FRACS, James Gallagher FRACS, Mike Hollands FRACS,
Tom Hugh FRACS, David Hunt FRACS, John Jorgensen
FRACS, Christopher Martin FRACS, Mark Richardson FRACS,
Type 2 diabetes and the risk of oesophageal adenocarcinoma?
RE Neale et al
797
British Journal of Cancer (2009) 100(5), 795–798 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yGarrett Smith FRACS, Ross Smith FRACS and David Storey
FRACS.
Queensland: John Avramovic FRACS, John CrEse FRACP, Justin
D’Arcy FRACS, Stephen Fairley FRACP, John Hansen FRACS, John
Masson FRACP, Les Nathanson FRACS, Barry O’Loughlin FRACS,
Leigh Rutherford FRACS, Richard Turner FRACS, Morgan Wind-
sor FRACS South Australia: Justin Bessell FRACS, Peter Devitt
FRACS, Glyn Jamieson FRACS and David Watson FRACS.
Victoria: Stephen Blamey FRACS, Alex Boussioutas FRACP,
Richard Cade FRACS, Gary Crosthwaite FRACS, Ian
Faragher FRACS, John Gribbin FRACS, Geoff Hebbard FRACP,
George Kiroff FRACS, Bruce Mann FRACS, Bob Millar FRACS,
Paul O’Brien FRACS, Robert Thomas FRACS and Simon Wood
FRACS.
Western Australia: Steve Archer FRACS, Kingsley Faulkner
FRACS and Jeff Hamdorf FRACS.
Type 2 diabetes and the risk of oesophageal adenocarcinoma?
RE Neale et al
798
British Journal of Cancer (2009) 100(5), 795–798 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y